The Technical Analyst
Ensysce Biosciences, Inc. [ENSC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ensysce Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.13% $0.547
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4.01 mill |
| EPS: | -4.69 |
| P/E: | -0.120 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 7.33 mill |
| Avg Daily Volume: | 0.583 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.120 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.487 - 0.607 ( +/- 10.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-02 | Gower Bob G | Buy | 90 287 | Common Stock |
| 2023-03-01 | Gower Bob G | Buy | 270 000 | Common Stock |
| 2023-02-28 | Gower Bob G | Buy | 109 300 | Common Stock |
| 2022-12-09 | Gower Bob G | Buy | 357 143 | Common Stock |
| 2022-12-09 | Gower Bob G | Buy | 714 286 | Warrants |
| INSIDER POWER |
|---|
| 98.92 |
| Last 80 transactions |
| Buy: 23 095 136 | Sell: 3 675 006 |
Forecast:
16:00 - $0.547
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.547
Forecast 2: 16:00 - $0.547
Forecast 3: 16:00 - $0.547
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.547 (-2.13% ) |
| Volume | 0.0588 mill |
| Avg. Vol. | 0.583 mill |
| % of Avg. Vol | 10.09 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ENSC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.170 | N/A | Active |
|---|
ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Latest Press Releases
2024-04-25 08:00:00 - Press Release
Ensysce Biosciences' Ceo Dr. Lynn Kirkpatrick Featured In Xtalks Clinical Edge Magazine
~ dr. kirkpatrick leads the company's unique response to effectively reduce prescription drug overdose and abuse ~ san diego, ca / accesswire / april 25, 2024 / ensysce biosciences, inc. (nasdaq:ensc) ("ensysce" or the "company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, highlights the company's ceo, dr. lynn kirkpatrick, in the latest quarterly edition of xtalks clinical edge magazine published on april 24, 2024. in the article, dr. kirkpatrick discusses ensysce's driving force to produce safe and effective drug products within the highly scrutinized opioid class, overcoming the challenges of operating in this space and the clever chemistry of the company's lead product, pf614 and its associated platforms taap™ and mpar®.
2024-04-19 08:00:00 - Press Release
Ensysce Biosciences' Presentation From The Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
~ webcast replay available on ensysce's investor relations website ~ san diego, ca / accesswire / april 19, 2024 / ensysce biosciences, inc. (nasdaq:ensc) ("ensysce" or the "company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the company's webcast presentation and discussion during the noble capital markets emerging growth virtual healthcare equity conference on april 17, 2024 is available on ensysce's investor relations website at ir.ensysce.com and can also be viewed here. dr. lynn kirkpatrick, ceo of ensysce presented a summary of the company's taap and mpar® technology and provided the current status of the two lead drug candidates, pf614 and pf614-mpar, an opioid with oral overdose protection.
2024-04-09 08:00:00 - Press Release
Ensysce Biosciences To Participate In The Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
San diego, ca / accesswire / april 9, 2024 / ensysce biosciences, inc. (nasdaq:ensc) ("ensysce" or the "company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose, today announced its participation in the noble capital markets emerging growth virtual healthcare equity conference. dr. lynn kirkpatrick, chief executive officer of ensysce, and dave humphrey, chief financial officer of ensysce, are scheduled to present on wednesday, april 17th at 2:00 pm eastern time.
2024-03-15 08:00:00 - Press Release
Ensysce Biosciences Reports Fourth Quarter And Full Year 2023 Financial Results
Corporate update call to be held thursday, march 21, 2024 at 11:00am et to discuss recent fda breakthrough therapy designation and phase 3 clinical plans san diego, ca / accesswire / march 15, 2024 / ensysce biosciences, inc. ("ensysce" or the "company") (nasdaq:ensc), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023. dr. lynn kirkpatrick, chief executive officer of ensysce, commented, "we are proud of the significant progress ensysce has made in 2023 both operationally and clinically for our lead pain therapeutic, pf614, and our overdose protection product, pf614-mpar.
2024-02-27 08:00:00 - Press Release
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
San diego, ca / accesswire / february 27, 2024 / ensysce biosciences, inc. (the "company") (nasdaq:ensc), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from the nasdaq stock market llc ("nasdaq"), as described in a decision dated february 26, 2024, that the company may continue its listing on the nasdaq capital market tier with an extension to may 13, 2024 in order to demonstrate compliance with the equity requirement in listing rule 5550(b)(1). about ensysce biosciences ensysce biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs.
Latest News
2024-02-06 08:00:00 - Accesswire
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference
~ PF614-MPAR recognized as potential medical breakthrough ~ SAN DIEGO, CA / ACCESSWIRE / February 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced they have been selected to present one of the top 12 best Flash Talks in the Trailblazer Session at the 2024 American Association of Pain Medicine (AAPM) Meeting on March 9th. Dr. William Schmidt, Chief Medical Officer of Ensysce, will present "Preventing Prescription Drug Overdoses: Clinical development of Trypsin-Activated Abuse Deterrent (TAAP) Opioids with Overdose Protection".
2024-01-25 08:00:00 - Accesswire
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting
SAN DIEGO, CA / ACCESSWIRE / January 25, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Geoff Birkett, Chief Commercial Officer of Ensysce, will present a poster entitled "PF614-MPAR: A Novel Trypsin Activated Abuse Protected (TAAP™) Extended-Release Oxycodone Prodrug with Overdose Protection" at the Annual National Institutes of Health (NIH) "Helping to End Addiction Long-term" (HEAL) Initiative Scientific Meeting being held on February 7 and 8, 2024, in Bethesda, MD. PF614-MPAR, the lead product under Ensysce's oral overdose protection platform, MPAR® (Multi-Pill Abuse Resistance), was just granted Breakthrough Therapy Designation by the U...
2023-09-05 08:15:00 - Accesswire
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, CA / ACCESSWIRE / September 5, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that its management has been invited to present at the H.C. Wainwright 25th Annual Global Investment Conference (the "conference") taking place in New York, NY on September 11-13, 2023.
2023-08-14 08:15:00 - Accesswire
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium
~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain and Next Generation Solutions ~ SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will host a luncheon symposium and present their recent clinical data at PAINWeek on September 7-8, 2023 in Las Vegas, NV. PAINWeek is the leading conference in the world dedicated to helping pain physicians and practitioners improve their clinical knowledge and results.
2023-06-27 08:05:00 - Accesswire
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
Featured Presentation on ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose' SAN DIEGO, CA / ACCESSWIRE / June 27, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that the company will be providing a poster presentation at the upcoming CRS (Controlled Release Society) 2023 Annual Meeting & Expo, titled ‘Development of a Multi-Pill Abuse Resistant Extended-Release Formulation to Prevent Opioid Overdose.' Chief Medical Officer, Dr. William Schmidt, will participate in the event, being held from July 24-July 28, 2023, at the Paris Hotel in Las Vegas, Nevada.
2023-05-09 14:06:13 - InvestorPlace
Why Is Ensysce Biosciences (ENSC) Stock Up 50% Today?
Clinical-stage biotechnology firm Ensysce Biosciences (NASDAQ: ENSC ) skyrocketed sharply on Tuesday, with shares at one point gaining 50% before settling to around 26% up. Management announced the completion of its opioid-based pain medication integrated with a novel overdose protection mechanism.
2023-04-19 09:25:00 - Accesswire
Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development
~ Global QUOTIENT LIFE SCIENCES Webinar Today, April 19, 2023 at 11:30am ET ~ SAN DIEGO, CA / ACCESSWIRE / April 19, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Company's CEO, Dr. Lynn Kirkpatrick will be participating in ‘Strategies for Achieving Regulatory Milestones Faster: An Ensysce Biosciences & Quotient Sciences Customer Case Study Demonstrating the Benefits of an Integrated Approach for Accelerating Development' today, April 19 2023, at 11:30am ET as a featured speaker. Ensysce Biosciences' PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose.
2023-02-14 08:00:00 - Accesswire
Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
SAN DIEGO, CA / ACCESSWIRE / February 14, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced a Poster Presentation will be presented by Geoff Birkett, Chief Commercial Officer of Ensysce, at the Annual NIH HEAL Meeting on February 22, 2023, in Washington, D.C. The HEAL initiative is an effort to improve prevention and treatment strategies for opioid misuse and addiction and to enhance pain management across NIH institutes.
2023-01-23 08:05:00 - Accesswire
Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational
SAN DIEGO, CA / ACCESSWIRE / January 23, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that Chief Executive Officer, Dr. Lynn Kirkpatrick, will present a company overview at the Diamond Equity Research 2023 Virtual Emerging Growth Invitational on Wednesday, January 25th, 2023, at 12:20 p.m. Eastern Time.
2022-12-19 09:33:00 - PennyStocks
Penny Stocks To Buy Now? 6 To Watch With Big News Today
